TFXNYSESurgical & Medical Instruments & ApparatusUS GAAP · USD

Teleflex Incorporated

Teleflex Inc. is a U.S.-based medical technology company that designs, manufactures, and supplies single-use devices used in critical care, surgical, and diagnostic procedures. Its portfolio serves hospitals and healthcare providers worldwide through direct sales and distributors, with manufacturing and operations spread across North America, Europe, and Asia.

Kysy yhtiöstä
Liikevaihto1 993milj. USD
+17,2 %v/v
Liikevoitto (EBIT)118milj. USD
+14,2 %v/v
EBIT-marginaali5,9%
−0,2 %-yks.v/v
Nettotulos−906milj. USD
−1 399,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

01 0002 0003 000milj. USD2020: 2 537 milj. USD2020: EBIT 423 milj. USD20202021: 2 810 milj. USD2021: EBIT 628 milj. USD20212022: 2 791 milj. USD2022: EBIT 500 milj. USD20222023: 2 974 milj. USD2023: EBIT 506 milj. USD20232024: 1 700 milj. USD2024: EBIT 104 milj. USD20242025: 1 993 milj. USD2025: EBIT 118 milj. USD20251 993118
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Teleflex Incorporated

Liiketoiminta

Osuus liikevaihdosta
Critical care devices30 %

Single-use products used in intensive care and emergent hospital procedures.

Surgical and diagnostic devices25 %

Devices used in common surgical and diagnostic procedures across hospitals.

Vascular access and catheters20 %

Catheters, access devices, and related products for interventional care.

Anesthesia and respiratory care15 %

Products supporting airway management, anesthesia, and breathing support.

OEM and specialty products10 %

Specialty-engineered and original equipment manufacturer products and components.

Tuotteet

Raportoitu · osuus liikevaihdosta
46,1%32,5%21,0%FY2025100 %
  • Vascular Access46,1 %
  • Interventional32,5 %
  • Surgical21,0 %
  • Other0,5 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Teleflex sells primarily to hospitals, healthcare systems, and other healthcare providers that use its devices in critical care and surgical settings. It also serves distributors and, in some product lines, original equipment and specialty channel customers. Demand is tied to procedure volumes, clinical adoption, reimbursement conditions, and the need for reliable single-use devices.

Hospitals and health systems

Buy single-use devices for critical care, surgery, and diagnostic procedures.

Healthcare providers and clinics

Purchase procedure-specific devices used across inpatient and outpatient care.

Distributors

Resell Teleflex products in markets where indirect channel coverage is needed.

OEM and specialty customers

Buy selected product lines or components for integration into broader offerings.

Strategia

Teleflex’s strategy centers on expanding its product portfolio, developing new products and line extensions, and broadening use of its technologies into new markets. The company also emphasizes manufacturing efficiency, selective acquisitions and partnerships, and portfolio optimization to strengthen its competitive position in hospital-based medical devices.

New product developmentKeskipitkä aikaväli

Fresh products and line extensions support share gains in procedure-based markets.

Geographic expansionKeskipitkä aikaväli

Entering new markets reduces dependence on any one region or procedure mix.

Operational efficiencyLyhyt aikaväli

Lower-cost manufacturing and distribution improve competitiveness in commoditized categories.

Portfolio optimizationKeskipitkä aikaväli

Divesting non-core businesses can sharpen focus on higher-priority medical device lines.

Maantiede

Teleflex sells worldwide and reports operating segments for the Americas, EMEA, and Asia Pacific. Manufacturing is concentrated in the Czech Republic, Malaysia, Mexico, and the United States, which supports a global supply chain but also creates exposure to cross-border logistics, currency movements, and regional procurement policies.

Riskit

Teleflex faces intense competition, product liability exposure, and regulatory risk because its devices are used in high-acuity clinical settings. It is also exposed to reimbursement pressure, supply chain disruption, cybersecurity risk, and foreign exchange or procurement-related pricing pressure in international markets.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Product liability and recall exposure1Intense medical device competition2Reimbursement and coverage pressure3Cybersecurity and IT disruption4Foreign exchange and procurement policy risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Product liability and recall exposureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Devices used on seriously ill patients can trigger claims if defects or labeling issues arise.

    KohdistuuCritical careSurgicalImplanted or invasive products
  2. Intense medical device competitionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Large and niche competitors can outspend Teleflex on development, marketing, and distribution.

    Kohdistuu: Product categories sold into hospitals and specialty procedures

  3. Reimbursement and coverage pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Customer purchasing decisions depend on third-party coverage and reimbursement levels.

    Kohdistuu: Hospital and provider purchasing channels

  4. Cybersecurity and IT disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Operational systems support ordering, invoicing, shipping, and customer relationships.

    Kohdistuu: Enterprise systems and third-party technology providers

  5. Foreign exchange and procurement policy riskVaikutus: KeskitasoTodennäköisyys: Matala

    International sales and China procurement programs can affect pricing and margins.

    Kohdistuu: Asia and other non-U.S. markets

Kysy Clarifolta: Teleflex Incorporated

Kirjanpito

Harkinnanvaraiset erät
Inventory valuation and obsolescence

Single-use devices and product line changes can create excess or obsolete inventory risk.

Vaikutus: Can affect cost of goods sold and gross profit through reserve adjustments

Restructuring charges

Footprint realignment and integration plans create employee, relocation, and facility costs.

Vaikutus: Affects operating expenses and period-to-period comparability

Foreign exchange derivatives

The company hedges foreign currency exposure tied to international operations and acquisitions.

Vaikutus: Can create mark-to-market gains or losses in earnings or OCI

Acquisition accounting

Purchased businesses bring fair value step-ups, intangibles, and integration-related estimates.

Vaikutus: Affects revenue mix, amortization expense, and goodwill/intangible balances

Product liability and warranty reserves

Medical devices can generate claims, recalls, and warranty obligations over time.

Vaikutus: Can materially affect operating expense and contingent liabilities

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Teledyne Technologies Incorporated

TDY · Search, Detection, Navigation, Guidance, Aeronautical Sys

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

Orthofix Medical Inc.

OFIX · Surgical & Medical Instruments & Apparatus

Terex Corporation

TEX · Industrial Trucks, Tractors, Trailors & Stackers

Stryker Corporation

SYK · Surgical & Medical Instruments & Apparatus

Medtronic plc

MDT · Electromedical & Electrotherapeutic Apparatus

Päivitetty: 24.9.2026

Teleflex Incorporated (TFX) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo